Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12561174 | 0.86 | GAA (0.45) | L3MBTL1KMT2APOLBCYP1A2MGAM | |
| SCHEMBL27649923 | 0.81 | CYP1A2 (0.44) | L3MBTL1KMT2APOLBCYP1A2MGAM | |
| SCHEMBL9957937 | 0.80 | ALDH1A1 (0.43) | L3MBTL1KMT2APOLBCYP1A2GAA | |
| SCHEMBL27276025 | 0.78 | L3MBTL1 (0.44) | L3MBTL1KMT2APOLBCYP1A2MGAM | |
| SCHEMBL6564298 | 0.77 | L3MBTL1 (0.42) | L3MBTL1KMT2APOLBCYP1A2MGAM | |
| SCHEMBL2888407 | 0.76 | L3MBTL1 (0.37) | L3MBTL1KMT2APOLBCYP1A2MGAM | |
| Succinic Acid Diethyl Ester SCHEMBL22780 | 0.76 | GAA (0.67) | L3MBTL1POLBCYP1A2MGAMGAA | |
| Succinic Acid Diethyl Ester SCHEMBL27768067 | 0.76 | GAA (0.67) | L3MBTL1POLBCYP1A2MGAMGAA | |
| SCHEMBL8213375 | 0.74 | L3MBTL1 (0.47) | L3MBTL1KMT2APOLBCYP1A2MGAM | |
| SCHEMBL28818362 | 0.74 | CYP1A2 (0.48) | L3MBTL1KMT2APOLBCYP1A2MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885726-B1 | ORTHO-CONDENSED 2-PYRIDINONE DERIVATIVES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20110152259-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PALANI ANANDAN | 2011-06-23 | — | — | US | disclosed |
| US-20100227873-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-09-09 | — | — | US | disclosed |
| US-20100227873-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-09-09 | — | — | US | disclosed |
| US-7750015-B2 | Nitrogen-containing heterocyclic compounds and methods of use thereof | SCHERING CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750015-B2 | Nitrogen-containing heterocyclic compounds and methods of use thereof | SCHERING CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-7737155-B2 | Nitrogen-containing heterocyclic compounds and methods of use thereof | SCHERING CORPORATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737155-B2 | Nitrogen-containing heterocyclic compounds and methods of use thereof | SCHERING CORPORATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-7723342-B2 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723342-B2 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2008060476-A2 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080019978-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080019978-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20070066630-A1 | Nitrogen-containing heterocyclic compounds and methods of use thereof | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066630-A1 | Nitrogen-containing heterocyclic compounds and methods of use thereof | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
| US-5026863-A | Medicinal products in racemic or enantiomorph form; calcium channel blockers. hypotensive agents, cardiovascular disorders | ADIR ET COMPAGNIE (FR) | 1991-06-25 | — | — | US | disclosed |
| US-4983740-A | Multistep; from 2- 2-/2-chloroethoxy/ethoxy!ethanol and potassium phthalimide | ADIR ET COMPAGNIE (FR) | 1991-01-08 | — | — | US | disclosed |
| US-4870091-A | CALCIUM CHANNEL BLOCKERS | ADIR ET CIE (FR) | 1989-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080019978-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1 | L3MBTL1 4607/4885KMT2A 3599/4885POLB 1857/4885 |
| US-20070066630-A1 | Nitrogen-containing heterocyclic compounds and methods of use thereof | CYP11B2, CYP11B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | L3MBTL1 4571/4885KMT2A 3657/4885POLB 1965/4885 |
| US-20110152259-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1 | L3MBTL1 4607/4885KMT2A 3599/4885POLB 1857/4885 |
| US-20100227873-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1 | L3MBTL1 4607/4885KMT2A 3599/4885POLB 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.